Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse

Alexandria University100 enrolled

Overview

The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion of therapy. This is called sustained virological response (SVR) which corresponds to cure of HCV infection as risk of later relapse is very small. SVR is important to achieve improvement in liver necroinflammation and fibrosis and to decrease complications of cirrhosis. Failing to achieve SVR after treatment requires another regimen for these experienced patients. Real-world data are always needed to evaluate and improve our practices. Here investigators aim to assess tolerability and efficacy of different regimens used for management of genotype 4 HCV relapse.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatitis C Relapse Antivirals

Interventions

directly acting antivirals

Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all patients with HCV relapse after sofosbuvir plus either Non-structural protein 5 A (NS5A) or protease inhibitor. Exclusion Criteria: * No exclusion criteria

Locations (1)

Alexandria University.

Alexandria, Egypt

RECRUITING

Outcomes

Primary Outcomes

Sustained virological response

Time frame: 12 weeks after completion of treatment

Central Contacts

Ahmed Kamal

CONTACT

01279734654 Ahmed.Kamal@alexmed.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.